BioLife Solutions (BLFS) and BioSig Technologies (BSGM) Head-To-Head Review

Share on StockTwits

BioLife Solutions (NASDAQ:BLFS) and BioSig Technologies (NASDAQ:BSGM) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, valuation, earnings and dividends.

Volatility and Risk

BioLife Solutions has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Comparatively, BioSig Technologies has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.

Institutional & Insider Ownership

41.2% of BioLife Solutions shares are owned by institutional investors. Comparatively, 3.9% of BioSig Technologies shares are owned by institutional investors. 38.5% of BioLife Solutions shares are owned by company insiders. Comparatively, 26.7% of BioSig Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares BioLife Solutions and BioSig Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioLife Solutions 17.01% 10.32% 9.64%
BioSig Technologies N/A -354.26% -284.49%

Analyst Recommendations

This is a summary of current ratings for BioLife Solutions and BioSig Technologies, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLife Solutions 0 0 4 0 3.00
BioSig Technologies 0 0 2 0 3.00

BioLife Solutions currently has a consensus target price of $17.75, suggesting a potential downside of 4.26%. BioSig Technologies has a consensus target price of $12.50, suggesting a potential upside of 78.32%. Given BioSig Technologies’ higher probable upside, analysts plainly believe BioSig Technologies is more favorable than BioLife Solutions.

Valuation and Earnings

This table compares BioLife Solutions and BioSig Technologies’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioLife Solutions $19.74 million 17.66 $3.27 million $0.14 132.43
BioSig Technologies N/A N/A -$17.25 million N/A N/A

BioLife Solutions has higher revenue and earnings than BioSig Technologies.

Summary

BioLife Solutions beats BioSig Technologies on 9 of the 10 factors compared between the two stocks.

BioLife Solutions Company Profile

BioLife Solutions, Inc. develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death. The company offers CryoStor cryopreservation freeze media products to mitigate temperature-induced molecular cell stress responses during freezing and thawing; and HypoThermosol FRS, a hypothermic storage and shipping media product to mitigate temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications. It also provides BloodStor freeze media products, such as BloodStor 55-5 and BloodStor 100 to cryopreserve stem and other cells isolated from umbilical cord and peripheral blood, and bone marrow; and cell thawing media, which offers Dextran and saline for washing cryopreserved cells and tissues to dilute or remove cryoprotectants. In addition, the company provides custom product formulation and packaging services. It markets its products to the regenerative medicine, bio-banking, and drug discovery markets, including cell and gene therapy companies, research institutions, hospital-based stem cell transplant centers, cell therapy contract manufacturing organizations, contract development manufacturing organizations, pharmaceutical companies, cord blood and adult stem cell banks, and hair transplant centers, as well as suppliers of cells to the drug discovery, toxicology testing, and diagnostic markets. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.

BioSig Technologies Company Profile

BioSig Technologies, Inc., a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. Its product is PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and catheter ablation procedures. It is also developing a library of software tools that are designed to be configured to fit the needs of electrophysiologists in various settings and for arrhythmia treatments. The company was founded in 2009 and is headquartered in Los Angeles, California.

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Analysts Expect Bank of Hawaii Co.  to Announce $1.38 Earnings Per Share
Analysts Expect Bank of Hawaii Co. to Announce $1.38 Earnings Per Share
Soarcoin 1-Day Trading Volume Tops $220.00
Soarcoin 1-Day Trading Volume Tops $220.00
Mason Graphite  Shares Up 5.6%
Mason Graphite Shares Up 5.6%
Continental Gold  Shares Up 0.7%
Continental Gold Shares Up 0.7%
Arcus Biosciences Inc  Short Interest Update
Arcus Biosciences Inc Short Interest Update
Hancock Whitney Corp  Given Average Rating of “Buy” by Analysts
Hancock Whitney Corp Given Average Rating of “Buy” by Analysts


 
© 2006-2019 Zolmax.